Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Lenvatinib Approved in Europe for Frontline HCC

August 23rd 2018

The European Commission has approved lenvatinib (Lenvima) as a first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma.

Expert Highlights Latest Immunotherapy Efforts in CRC

August 23rd 2018

Michael J. Overman, MD, discusses the current state of immunotherapy in patients with CRC and how to optimally manage immune-related adverse events.

Dr. Shiller Discusses Molecular Testing in Gastrointestinal Cancers

August 22nd 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses molecular testing in gastrointestinal cancers.

Expert Navigates Through Expanding Therapeutic Options in NETs

August 21st 2018

Scott Paulson, MD, discusses recent updates in the treatment of patients with neuroendocrine tumors.

Dr. Paulson on When to Consider Lutathera in Patients With NETs

August 21st 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses when to consider using Lutathera (lutetium Lu 177 dotatate) in patients with neuroendocrine tumors (NETs).

Dr. McCollum on Frontline Therapy for Patients With Metastatic CRC

August 21st 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses frontline therapy for patients with metastatic colorectal cancer (mCRC).

Dr. Becerra Discusses Regorafenib Dosing in Metastatic CRC

August 20th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer.

Master of the Whipple Gave Hope, Extended Lives

August 19th 2018

John L. Cameron, MD, is most commonly associated with the refinement of Whipple procedures; these extensive surgical operations became far more successful thanks to his dedication.

Dr. Bekaii-Saab Discusses the FDA Approval of Lenvatinib in HCC

August 16th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the FDA approval of lenvatinib (Lenvima) as a frontline systemic treatment for patients with advanced hepatocellular carcinoma (HCC).

FDA Approves Lenvatinib for Frontline HCC

August 16th 2018

The FDA has approved lenvatinib as a first-line treatment for patients with unresectable hepatocellular carcinoma.

Dr. Ahn on Biomarker-Driven Strategies in Gastric/GEJ Cancers

August 15th 2018

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses biomarker-driven strategies in gastric and gastroesophageal junction (GEJ) cancers.

Barr Bridges Past and Present Treatment of Neuroendocrine Tumors

August 15th 2018

Jodie Barr, DO, discusses the evolution of treatment of patients with neuroendocrine tumors and the need for biomarkers.

Dr. Bekaii-Saab Discusses the Evolution of Treatment for Pancreatic Cancer

August 14th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the evolution of treatment for patients with pancreatic cancer.

Expert Highlights Assay to Determine Patients With Lung, Gastrointestinal Cancers to Receive Pembrolizumab

August 10th 2018

The PD-L1 immunohistochemistry 22C3 pharmDx can be an aid in identifying patients with non–small cell lung cancer and gastrointestinal cancers who are eligible for pembrolizumab (Keytruda) monotherapy.

Eng Expands on Evolving GI Cancer Landscape

August 9th 2018

Cathy Eng, MD, highlights recent data that could shape the treatment landscape for several gastrointestinal cancers.

Dr. Shah Discusses the BRIGHTER Study in Gastric Cancer

August 9th 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the BRIGHTER study in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Yezefski on Differences in CRC Care Costs Between the US and Canada

August 9th 2018

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, discusses the differences between colorectal cancer care costs in the Unites States and Canada.

Shah Shares Immunotherapy, STAT3 Inhibitor Data in GI Cancers

August 8th 2018

Manish A. Shah, MD, shares insight on the challenges that remain in the treatment of esophageal and gastric cancers.

Dr. Finn Discusses Sequencing Therapy for HCC

August 7th 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses sequencing therapy for patients with hepatocellular carcinoma.

FDA Grants Novel Triplet Breakthrough Designation in BRAF+ mCRC

August 7th 2018

The FDA has granted a breakthrough therapy designation to the combination of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer.